Bouri Sara, Hanane Hanane, Idrissi Khadija El Ayoubi, Berraho Mohamed Amine, Abdellaoui Abdelfattah, Badiaa Lyoussi, Rammouz Ismail, Achour Sanae
Department of Biology, Sidi Mohamed Ben Abdellah University, Laboratory of Physiology-Pharmacology & environmental Health, Faculty of Science Fez, BP 1796 Fez-Atlas 30003, Morocco.
Department of Psychiatry, University Hospital Hassan II Fez,BP 1893, road of Sidi Hrazem Fez 30000, Morocco.
Avicenna J Phytomed. 2020 Jan-Feb;10(1):89-100.
Cannabis use is considered a major clinical problem associated with a poorer outcome in patients with schizophrenia. The objective of the present study was to assess the prevalence of cannabis us among patients with schizophrenia. The assessment consists in comparing some factors related to substance use in a population of schizophrenic patients between cannabis users and non.
Four hundred and three participants who were examined prospectively during their hospitalization answered the PANNS scale of schizophrenia, GAF, BIS-10, CDSS, and MARS. The consumption of cannabis was investigated using urine toxicological analysis. Sociodemographic, clinical and therapeutic data were also recorded.
The prevalence of cannabis use among schizophrenic inpatients was 49%. Patients with cannabis use were younger (31.7 vs 34.9 years old, p<0.001), more often male (52 vs 20% female, p<0.001), and they presented more often a history of imprisonment (68.8% vs 31.2%, p<0.001). Patients who were users of cannabis had a lower age at onset of the disease than non-users (23.6 vs 24.8 years, p=0.029), and more often with poor medication adherence (p=0.001). Logistic regression revealed that factors associated with cannabis use among schizophrenics were the age, gender, history of imprisonment and poor medication adherence.
The study showed that a high prevalence of cannabis use among patients with schizophrenia which was associated with negative overall outcomes. Determining comorbid substance use disorders among schizophrenic patients is crucial as it may contribute to establish a better therapeutic strategy.
大麻使用被认为是与精神分裂症患者较差预后相关的一个主要临床问题。本研究的目的是评估精神分裂症患者中大麻使用的患病率。评估包括比较大麻使用者和非使用者这两类精神分裂症患者人群中与物质使用相关的一些因素。
403名在住院期间接受前瞻性检查的参与者回答了精神分裂症的PANNS量表、GAF、BIS - 10、CDSS和MARS。使用尿液毒理学分析调查大麻的消费情况。还记录了社会人口统计学、临床和治疗数据。
精神分裂症住院患者中大麻使用的患病率为49%。使用大麻的患者更年轻（31.7岁对34.9岁，p<0.001），男性更常见（52%对女性20%，p<0.001），并且他们有监禁史的情况更常见（68.8%对31.
